CA
TLSI icon

Clearstead Advisors’s TriSalus Life Sciences TLSI Stock Holding History

Clearstead Advisors’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$455 Buy
+100
New +$397 ﹤0.01% 2951

Other funds holding TLSI

FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WPC
White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

Clearstead Advisors's TLSI Position: Q2 2026 in Review

Clearstead Advisors opened a new position in TriSalus Life Sciences (TLSI) in Q2 2026: 100 shares worth $455. The stake represents ﹤0.01% of the portfolio and ranks #2951 among its holdings.

79 funds tracked by Wall St. Rank hold TLSI as of Q2 2026.

  • Clearstead Advisors held 100 shares of TriSalus Life Sciences worth $455 as of Q2 2026.
  • TriSalus Life Sciences was a new Clearstead Advisors position in Q2 2026.
  • TriSalus Life Sciences made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2951 holding.
  • 79 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.